Purpose: The purpose of this study was to test whether basic fibroblast growth factor (bFGF) participates in arterialized vein graft remodeling. Methods: Rabbits underwent in vivo gene transfer and carotid interposition vein grafting. Segments of external jugular vein were infected with an adenovirus that expressed antisense bFGF RNA (Ad.ASbFGF) at 1 × 10 10 PFU/mL to inhibit new synthesis of bFGF by cells in the vein graft wall. Control rabbits were treated with either adenovirus that encoded β-galactosidase (Ad.lacZ) at 1 × 10 10 PFU/mL or vehicle (phosphatebuffered saline solution [PBS]). At 3 days, 3 grafts per treatment group were harvested for the determination of gene expression of ASbFGF RNA by reverse transcriptasepolymerase chain reaction. Rabbits were killed, and perfusion was fixed 2 months after the grafting. Total wall thickness and lumen circumference of vein grafts and normal arteries were measured in cross sections. Calculated mean tangential stress (±SD) for the ASbFGF-treated group and controls was compared for significance. Grafts were immunohistochemically stained to assess bFGF protein production. Results: Only the grafts infected with the Ad.ASbFGF gene expressed ASbFGF RNA. Grafts that were treated with Ad.ASbFGF displayed lower tangential stress (10.9 ± 2.3 dynes/cm 2 ) than PBS alone (22 ± 2.8 dynes/cm 2 ) or Ad.lacZ-treated controls (20.6 ± 5.4 dynes/cm 2 ; P < .001). Tangential stress in the Ad.ASbFGF group was comparable to a normal carotid artery (13.9 ± 2.1 dynes/cm 2 ). The difference in mean total wall thickness was significant among the 3 treatment groups: Ad.ASbFGF, 164 ± 3.4 µm); Ad.lacZ, 100 ± 3.3 µm; and PBS, 96 ± 3.6 µm; P < .01). Luminal circumference was not different among the groups. The Ad.ASbFGF-treated vein graft wall was composed of thick layers of concentric smooth muscle cells and elastin fibers in contrast to the sponge-like appearance observed in control arterialized vein grafts. Reduction in bFGF protein was noted only in the Ad.ASbFGF-treated group. Conclusion: Inhibition of bFGF synthesis in vivo with the use of adenoviral gene transfer of antisense RNA to bFGF promotes a vein graft with decreased tangential stress while maintaining the luminal area. The vein graft wall is remodeled and qualitatively resembles an artery so that wall tangential stress in Ad.ASbFGF and normal artery are not significantly different. The lack of significant difference in lumen circumference among groups suggests that wall thickening in the Ad.ASbFGF grafts is not at the expense of luminal narrowing. Our results suggest that ASbFGF RNA expression may represent an effective strategy in limiting the failure of arterialized venous conduits. (J Vasc Surg 2000;31:770-80.)
Vein bypass grafting restores blood flow to a compromised vascular bed, and it leads to the thickening of the vein graft wall. [1] [2] [3] [4] In response to arterial pressures and pulsatile flow, the vein graft undergoes an adaptive remodeling process to strengthen the normally thin vein wall. Exaggeration of this process in the neointima causes failure of the vein graft as a conduit. The ideal remodeling process for arterialized veins would preserve luminal dimensions, while thickening the wall with smooth muscle cells (SMCs) and elastin fibers. Furthermore, the SMCs and elastin fibers would be arrayed concentrically for maximal passive and active responses to pulsatile flow. Thickening of the vein graft wall may serve to minimize tangential stress. 4, 5 In this regard, the ideal proportions of lumen radius to wall thickness are those of a normal artery.
In animal arterialized vein graft (AVG) models, intimal hyperplasia develops rapidly, with SMC proliferation peaking at 1 week and becoming quiescent at 3 to 6 months. Because SMC mass does not increase after 4 weeks after grafting, further increases in wall thickness (observed between 1 and 3 months) are accounted for by the accumulation of extracellular matrix. 4 The tissue remodeling process is modulated by growth factors. Immunocytochemical evidence indicates that basic fibroblast growth factor (bFGF) and platelet-derived growth factor are upregulated in injured arteries and AVGs. 6 Although the upregulation of bFGF in newly grafted vein segments is documented, the significance of continued de novo bFGF synthesis in AVG walls remains unknown. [7] [8] [9] We previously tested the possible role of bFGF in remodeling by inhibiting bFGF production by the administration of antisense bFGF RNA (ASbFGF) in a rat aortic SMC culture and in an in vivo model of injured carotid artery. 10, 11 In cell culture, antisense RNA administered through the adenoviral vector (Ad.ASbFGF) reduced cellular bFGF content and decreased the growth rate of SMC in a doserelated manner. In addition, ASbFGF altered the SMC phenotype and appeared to stimulate apoptosis, as indicated by positive terminal tdt-deoxyuridine nick-end labeling reaction. 10 In Fogarty-balloon-injured carotid arteries, administration of a single dose of ASbFGF at the time of injury resulted in decreased neointima formation and the restoration of the media and was dose dependent. 11 To test the hypothesis that the inhibition of bFGF synthesis will beneficially alter the remodeling process, we extended our studies to an in vivo model of a vein interposition graft in this work. We rea-soned that adenovirally mediated delivery of antisense bFGF RNA at the time of grafting would block new synthesis of bFGF, providing us with a research tool to study the molecular and cellular events of bFGF-dependent AVG remodeling and perhaps lead to an effective therapeutic intervention.
METHODS

Rabbit model of interposition vein graft and in vivo gene transfer. Fifty-one adult male New
Zealand White rabbits that weighed 3 ± 0.1 kg were anesthetized with an intramuscular injection of ketamine (50 mg/kg; Aveco Co, Fort Dodge, Iowa), xylazine (5 mg/kg; Mobay Corp, Shawnee, Kan), and acepromazine (1 mg/kg; Aveco Co). Neither mechanical ventilation nor supplemental intravenous fluid administration was required. Twelve AVGs were constructed to study the time course of bFGF RNA expression in untreated grafts, although 39 vein grafts received treatment before the grafting.
Common carotid AVGs were performed according to published reports. 4 Briefly, a 2.5-cm segment of the external jugular vein, lacking valves, was isolated by ligation of the proximal and distal vein. A small venotomy was made in the distal vein. After irrigation with phosphate-buffered saline solution (PBS), a 250 µL volume of either adenoviral vector (at 1 × 10 10 PFU/mL) in PBS or PBS alone was injected into the lumen of the isolated vein and maintained at 120 mm Hg pressure for 30 minutes.
After systemic heparinization (1000 U; Elkins-Sinn Inc, Cherry Hill, NJ), the carotid artery was dissected and clamped. A segment of carotid artery, equal to the original in situ length of the vein segment, was excised. The vein segment, free of surrounding tissues, was grafted by end-to-end anastomoses with a 9-0 nylon continuous running suture (Sharpoint Surgical Specialties Corp, Reading, Pa). Arterial blood flow was restored to the carotid artery and vein graft. The neck incision was closed in two layers, and the animals were placed under a warming light until fully recovered from anesthesia. After recovery, the rabbits were fed a normal diet and water as desired. Animal care complied with the "Principles of Laboratory Animal Care" formulated by the National Society of Medical Research, and the "Guide for the Care and Use of Laboratory Animals" (NIH publication no 86-23, revised 1985).
Construction of Ad.ASbFGF
Recombinant adenoviruses. The Ad.ASbFGF replication-defective recombinant adenovirus was constructed by replacement of the β-galactosidase cDNA with a 1.1 kbp rat bFGF cDNA that contained the entire coding sequence in reverse orientation (gift of Dr Andrew Baird, Whittier Institute) 12 in the plasma AD.CMV laZ (Ad.lacZ) shuttle vector (gift of Dr James Wilson, University of Pennsylvania) followed by homologous recombination 13 with the E1, E3-deleted, human adenovirus serotype 5 mutant dl7001 14 in human embryonal kidney 293 cells (American Type Culture Collection, Bethesda, Md). Recombinant virus was identified by polymerase chain reaction (PCR) amplification of recombinant plaques with the use of one vector-specific and one insert-specific primer. The vector-specific primer (5´-AGA-CAT-GAT-AAG-ATA-CAT-3´) corresponds to a region of the plasmid shuttle vector upstream of the insert cloning site but contains no adenoviral genomic sequence. The insert-specific primer (5´-GCT-TCT-TCC-TGC-GCA-TCC-3´) corresponds to codons 37 to 42 of the rat bFGF coding sequence. The recombinant virus was twice plaque-purified, and the expression of the antisense transcript was confirmed by reverse transcriptase PCR (RT-PCR). The PCR was performed with 1 U per reaction of Taq polymerase (Boehringer Mannheim Corp, Indianapolis, Ind) in a thermal cycler (Ericomp Inc, San Diego, Calif) for 25 cycles with 1-minute steps. The denaturation was performed at 94°C; the annealing was performed at 60°C, and the extension was performed at 72°C.
Ad.lacZ was used as the viral vector control in these experiments. The suspension vehicle (PBS Bio-Whittaker, Walkersville, Md) served as the second control. Adenovirus that carried a cassette that encoded bFGF was not used as a control because it produces a protein with biologic effects. Importantly, the RNA produced by Ad.ASbFGF serves as an effective block of bFGF protein synthesis as demonstrated in SMC culture by Western immunoblot analysis. 10
Experimental groups
RNA was extracted from grafts harvested at 2 days, 1 week, 2 weeks, and 4 weeks to study the time course of bFGF expression in untreated AVGs. Three grafts were harvested for each time point. Ungrafted veins and carotid arteries were obtained at the time of death from the 2-day rabbits.
Animals were randomly assigned to three treatment groups (one experimental and two control groups) to test whether antisense bFGF RNA had an effect on vein graft wall remodeling. Each treatment group consisted of 13 rabbits that received either Ad.ASbFGF at 1 × 10 10 PFU/mL, Ad.lacZ at 1 × 10 10 PFU/mL, or PBS (vehicle only). The dose of Ad.ASbFGF was chosen because it provides beneficial effects in a carotid artery injury model. 11
Analysis of bFGF RNA time-course in untreated AVGs
Untreated AVGs were harvested at 2 days, 1 week, 2 weeks, and 4 weeks and snap-frozen in liquid nitrogen. Ungrafted jugular veins and normal carotid arteries were also harvested. Samples were homogenized, and the RNA was extracted with RNAzol B according to the manufacturer's instructions (Biotecx Laboratories, Houston, Texas). Total tissue RNA (2 µg) was heat denatured (65°C for 5 min) and reversetranscribed with 0.1 µg of random hexamer primers (Boehringer Mannheim Corp) and 400 units of Moloney murine leukemia virus reverse transcriptase (Gibco BRL, Gaithersberg, Md). Incubation was for 1 hour at 37°C in 50 µL reverse transcriptase buffer. The reaction was terminated when the mixture was heated to 95°C for 10 minutes.
All cDNA products were amplified with 0.25 µg of each primer and 25 units of Taq DNA polymerase (Boehringer Mannheim Corp). Normal carotid artery served as the positive control, and RNA-free water served as negative control. The sequences of the human bFGF primers were as follows, 5Á CCATGGCAGCCGGGAGCATCACCACGCTG 3´ (sense) and 5´ CAGCTCCTTAGCAGACATTG-GAAGAAAAAG 3´ (antisense). These primers are predicted to amplify a 471-bp fragment. PCR was performed in a thermal cycler (Perkin Elmer 9600; Perkin Elmer, Norwalk, Conn) for 35 cycles with 30-second steps. Denaturation was performed at 94°C; annealing was performed at 58°C, and extension was performed at 72°C. An aliquot of each amplification mixture was subjected to electrophoresis on 2% agarose gel and was visualized by the Southern blot technique.
Tissue preparation and analysis
X-gal chromagen staining. Two animals from each treatment group were killed at 4 days after the grafting procedure. Tissue samples were quickly harvested, rinsed of blood, embedded in OCT compound (Miles Inc, Elkhart, Ind), and frozen with dry ice. The uninjured right external jugular veins served as negative controls for gene transfer.
β-Galactosidase activity, an index of successful Ad.lacZ infection, was documented with X-gal chromagen in interposition AVG specimens. Vein graft samples were thawed and rinsed with PBS to remove OCT. The tissues were immersed in PBS for 20 min-utes, then fixed in 2.5% glutaraldehyde (Fisher Scientific, Fair Lawn, NJ) for 15 minutes. Samples were rinsed twice in 1 mmol/L MgCl-PBS before incubation with the X-gal chromagen mixture (5-Bromo-4-chloro-3-Indolyl-β-D-galactopyranoside; Fisher Scientific, Malvern, Pa) for 1 hour at 37°C. Cross-section and enface preparations were examined at ×10 and ×25 with a Leitz dissecting photomicroscope (Leica Inc, Malvern, Pa).
After X-gal chromagen staining, a segment of vein was also fixed in 10% formalin and embedded in paraffin. Eight micrometer-thick cross section samples were cut from the paraffin blocks, counterstained with hematoxylin, then examined at ×250 magnification (Leitz Laborlux-s; Leica Inc) for evidence of intracellular production of β-galactosidase. Tissues that stained positive for β-galactosidase contained blue cytoplasmic inclusions. Only blue staining adjacent to a nucleus was counted as a β-galactosidase positive cell to avoid overestimation of efficiency. Results were recorded as percent efficiency of transgene expression. The mean percent efficiency of transgene expression was calculated by averaging the number of β-galactosidase positive cells divided by the number of total cells in the intima and media per ×250 field. Determinations were made at six randomly chosen sites on each cross section with reference to position on a clock face. Four individual cross sections were examined per AVG, and two separate AVGs were examined per treatment group.
Documentation of ASbFGF gene transfer to arterialized vein graft tissue. Confirmation of successful vein graft infection by the Ad.ASbFGF vector was documented with RT-PCR. Ad.ASbFGF-and Ad.lacZ-infected grafts were harvested 3 days after the experimental procedures. Naive ungrafted, uninfected anterior jugular vein served as a negative tissue control. The complement DNA plasmid encoding the antisense bFGF sequence that was used initially to make the Ad.ASbFGF vector served as the PCRpositive control. RT-PCR was performed with the following steps: 1. RT: Three AVGs from each vector-treated group and normal vein were weighed and homogenized with Trizol (1 mL per 50-100 mg tissue; Gibco-Life Science, Gaithersburg, Md). Manufacturer's instructions were followed for phase separation, RNA precipitation, and redissolution of the RNA. Ultraviolet spectrophotometry at 260 nm and 280 nm was used to measure the RNA concentration and purity of each sample. Total tissue RNA (3 µg) was heat denatured (65°C for 5 min) and reverse-transcribed with 1 µmol of a sequence-specific primer. This primer contains 18 bases (5´-ACTTCGCTTCCCGCACTG-3´) of bFGF sequence complementary to the antisense strand (corresponding to codons 7-12 of 18-kD rat bFGF at the 3´ end and a 30-base random sequence at the 5´ end (5´-CTTATACG-GATATCCTGGCAATTCGGACTT -3´). The 5´ random sequence tag permits subsequent PCR amplification with a specific primer that corresponds to this tag sequence, thus rendering the overall amplification both strand-specific and adenovirally mediated RNA specific. RT was performed in a final reaction volume of 30 µL with the use of 20 units of RT (Perkin Elmer). Incubation conditions for RT were 15 minutes at 42°C, 30 minutes at 37°C, and 5 minutes at 95°C in a thermal cycler (Perkin Elmer 480; Perkin Elmer). 2. PCR: All cDNA products were amplified with 1 pmol of the tag sequence plus 1 pmol of a specific primer for 18-kD reverse bFGF codons. Antisense bFGF cDNA plasmid served as the positive control. Normal vein and RNA-free water served as negative controls. The target RT products were amplified with 1 pmol each of the tag primer plus the primer sequence (that was described earlier) in the tissue RT reaction. The PCR was performed in a 20 µL volume with 1 unit per reaction of Taq polymerase (Perkin Elmer) in a thermal cycler (Perkin Elmer 9600; Perkin Elmer) for 25 cycles with 1-minute steps (Perkin Elmer). Denaturation was performed at 94°C; annealing was performed at 60°C, and extension was performed at 72°C. Products were separated on an agarose gel and visualized by ethidium bromide staining with a digital imaging system (IS-1000; Alpha Innotech Corp, San Leandro, Calif). If ASbFGF transcript is present, a 428-bp PCR product should be identified. 15 Formalin fixation. The remaining eight animals in each treatment group were killed at 3 weeks (n = 3 animals) or 2 months (n = 5 animals) after injury. At these times, the vessels were perfusion fixed in situ at a perfusion pressure of 100 to 110 mm Hg. Normal saline solution was instilled first and followed by 10% formalin solution through a large-bore cannula that was placed retrograde in the thoracic aorta. The carotid arteries that contained the interposition vein grafts were harvested en bloc for further immersion fixation. The samples were embedded in paraffin then processed with either hematoxylin-eosin or elastin-collagen stain. All chemicals were of analytic-grade quality.
April 2000 BFGF immunohistochemistry. Three samples from the 3-week-old groups and five samples from the 2-month-old groups were analyzed for the presence of bFGF protein. Three-week-old AVGs were evaluated because the adenoviral vector is almost completely absent after 10 to 14 days. At 3 weeks, the grafts have the morphologic characteristics that persist at least up to 2 months. However, the effect of the antisense RNA on bFGF synthesis may still be noticeable at 3 weeks.
Paraffin-embedded 6-µm thick cross sections were deparaffinized in xylene and hydrated through graded ethanol baths. The slides were prepared in the microwave in SMC 1X buffer (Promega Corp, Madison, Wis) for 30 seconds and left in the hot solution for 30 minutes. Antigen retrieval was performed with 0.2% hyaluronidase (Sigma Corp, St Louis, Mo) in PBS at 37°C for 30 minutes. Endogenous peroxidase was blocked with 3% H 2 O 2 for 10 minutes. Primary antibody to bFGF at a dilution of 1:100 (Upstate Biotechnology, Waltham, Mass) was incubated at room temperature for 2 hours. Biotinylated goat-anti-mouse secondary antibody was incubated at room temperature for 30 minutes (BioGenex, San Ramon, Calif). Application of the horseradish peroxidase label and chromagen developer was as per instructions in the detection kit (BioGenex "Supersensitive": BioGenex).
Morphometric analysis of the AVG wall
Tangential stress (lumen radius to wall thickness ratio). Morphometric analysis was performed on AVG cross sections. Measurements were performed with a light microscope (Leitz Laborlux-s; Leica Inc), fitted with a computer-interfaced image analyzer (Bioquant System IV; R&M Biometrics Inc, Nashville, Tenn; and Summa Sketch II Plus; Summagraphics Corp, Seymour, Conn). The circumference of the AVG lumen was directly measured at a magnification of ×50. Three separate cross sectional samples (proximal, mid, and distal regions) were measured from each graft to determine the luminal radius.
Mean tangential stress across the wall may be estimated from the LaPlace law τ T = Pr/h, where τ is tangential wall stress, P is systemic pressure, r is luminal radius, and h is vessel wall thickness. If blood pressure is constant, then mean tangential stress is proportional to the r/h ratio. 4 Wall thickness measurement. Total wall thickness was measured at nine sites (at designated clock positions) on each cross section sample. Three cross sectional samples were evaluated for each graft (one each from the proximal, mid, and distal AVGs). The mean wall thickness was calculated by averaging the thickness of the nine sites on each cross section then averaging the results of the three cross sections from each AVG. Wall thickness was defined as the region from the lumen up to where abluminal microvessels were observed (the adventitia). An arbitrary number was assigned to each sample, thereby blinding the person performing the measurements to the treatment and original sample designation. All measurements were performed in duplicate.
Statistical analysis
Data were calculated for each group as mean ± SD of the mean and were compared with one another by analysis of variance, followed by the Tukey method of post hoc pair-wise testing. The data were computed with the Systat 5.01 for Windows software (Systat Incorporated, Evanston, Ill). A P value of .05 or less was considered significant. 6). Note that bFGF RNA is not detectable in native jugular vein and in the 2-day-old graft. It is present at 1 week and thereafter. The results are not quantitative because the goal of the study was simply to demonstrate the detection of or the lack of RNA (cDNA products). Lane overloading is responsible for the cDNA product smear observed in some lanes. carotid arteries contain messages for bFGF, although RNA for bFGF was not detected in native jugular vein or in the jugular vein graft at 2 days after grafting. There is detectable upregulation of bFGF RNA in the grafted veins at 1 week after grafting and thereafter.
RESULTS
Time course of bFGF upregulation in AVGs.
Ad.lacZ transgene expression. AVGs, processed with X-gal chromagen for β-galactosidase, demonstrates excellent gene transfer with Ad.lacZ (Fig 2, A) . Sixty-five percent of AVG intima and media cellular elements stained positively for β-galactosidase activity (Fig 2, B) . Positive X-gal chromagen reaction was detected in the cells of the media and extended transmurally, in some sites, deeply into the bordering adventitia. This observation demonstrates the depth of AVG wall penetration achieved by adenovirally mediated gene transfer. Endogenous β-galactosidase activity was not detected in PBS or Ad.ASbFGF-treated AVGs or in native vein.
Ad.ASbFGF transgene expression and its impact on bFGF production. Gene expression of an ASbFGF RNA at 3 days after infection and grafting was noted only in the Ad.ASbFGF-treated grafts and not in control samples (Fig 3) . Both Ad.ASbFGF-treated grafts and plasmid cDNA (positive control) yielded an identical cDNA product (428 bp), although Ad.lacZ and PBS did not show ASbFGF RNA expression. Expression of ASbFGF RNA in the AVGs reduced bFGF protein expression at 3 weeks (Fig 4,  A) relative to control (Fig 4, B) . Because the ASbFGF is degraded by day 14, there is a more modest reduction of bFGF protein expression in the AVGs treated with Ad.ASbFGF (Fig 4, C) relative to control at 2 months (Fig 4, D) .
Vein graft wall histologic features. A hallmark of AVG is wall thickening. The difficulty in unequivocally identifying the internal elastic lamina and the inconsistent demarcation of the external elastic lamina precluded us from accurately measuring neointima and 
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April 2000 media separately. The presence of capillaries and other vascular structures located only in the adventitia served as the operational criteria for the determination of the medial/adventitial border in all these grafts.
The neointima of the PBS and Ad.lacZ-treated AVGs appeared granular (with elastin fibers, cells, and matrix oriented at arbitrary angles to each other; Fig 5, A and B) . In contrast, Ad.ASbFGF-treated grafts thickened by developing layers of circumferentially oriented SMCs and elastin fibers, much like that seen in normal arteries. It is not clear whether these parallel SMCs occupy space in the "neointima" or are a component of the media (Figs 5, C, and 6) .
Statistical analysis for tangential stress, wall thickness, and lumen circumference. There was a significant difference in mean total wall thickness among the three treatment groups (Ad.ASbFGF, 164 ± 3.4 µm; Ad.lacZ, 100 ± 3.3 µm; and PBS, 96 ± 3.6 µm; P < .1; Table I ). There was no significant difference in mean lumen circumference among the treatment groups (Table II) , which implied that wall thickening does not occur at the expense of luminal diameter. Grafts treated with Ad.ASbFGF displayed lower tangential stress ratio (10.9 ± 2.3 dynes/cm 2 ) when compared with PBS alone (22 ± 2.8 dynes/cm 2 ) or Ad.lacZ-treated controls (20.6 ± 5.4 dynes/cm 2 ; P < .001). Tangential stress in the Ad.ASbFGF group is comparable to normal carotid artery (13.9 ± 2.1 dynes/cm 2 ; Table III) .
DISCUSSION
Our study demonstrates that the inhibition of bFGF synthesis in AVGs, with the use of an antisense RNA gene strategy, significantly decreases tangential wall stress. This reduction is effective and has potential physiologic significance because the Ad.ASbFGFtreatment of AVGs changes the calculated tangential wall stress to be comparable to that of normal carotid arteries.
The reduction in calculated wall stress in Ad.ASbFGF-treated AVGs is most likely the result of the thickening of the vein wall. This morphologic change is an element of the adaptive response of interposition vein grafts to the sudden alteration in normal stress and is characterized by thickening as the result of SMC proliferation and extracellular matrix deposition. 4, 16 In our study, mean wall thickness was significantly increased in Ad.ASbFGF-treated veins relative to PBS-and Ad.lacZ-treated grafts, although the lumen, and therefore the radius, remained comparable in all the groups. In addition, thickening of the ASbFGF-treated AVGs occurred with the cellular and matrix fibers aligned concentrically around the lumen, whereas this pattern was absent in Ad.lacZ-and PBS-treated AVGs. In agreement with earlier reports, 4, 16 vein wall thickening in the rabbit AVG appears to occur without compro- mising lumen diameter. Our results confirm this form of tissue remodeling in rabbit interposition AVGs. In addition, our data advance the concept that early inhibition of bFGF provides potentially beneficial effects on tissue remodeling. Earlier reports showed upregulation of bFGF in injured arteries. 9 We reasoned that augmentation of gene expression of bFGF may also occur in interposition AVGs. We examined the level of RNA for bFGF in untreated-AVGs and demonstrated here that indeed bFGF is upregulated after grafting.
Interestingly, the levels of bFGF RNA are undetectable in naive jugular vein, and upregulation takes longer than 2 days after grafting. Our work and the work of others 16 have established that untreated AVGs in animal models will degenerate in time, which has been noted also in human autogenous vein grafts. 17 However, normal rabbit carotid arteries show significant levels of bFGF, as do maturing untreated AVGs (Fig 1) . These apparently opposite observations lead to the hypothesis that bFGF may play different roles in normal arteries and in remod- eling AVGs. One would speculate that bFGF may participate actively in the remodeling of arteries in response to high shear stress and pulsatile flow. On the other hand, observations in tissue culture indicate that ASbFGF inhibits the growth rate of ASbFGF-infected SMCs in a dose-dependent fashion. 10 Furthermore, those observations suggested that ASbFGF may have led to apoptosis in tissue culture, as indicated by TUNEL reaction and by gel electrophoresis. Importantly, supplementing the growth medium with recombinant bFGF can restore the SMC growth rate. 10 However, the molecular mechanisms of action of inhibition of bFGF on AVGs are not the subject of our current report. Success of transfection of antisense bFGF RNA in our study was demonstrated indirectly by β-galactosidase activity and directly by the presence of a 428-bp cDNA product by RT-PCR and by the inhibition of bFGF protein synthesis in AVGs at 3 weeks and at 2 months after the transfection and grafting. These findings support the existence of a cause-effect relationship between inhibition of bFGF and the observed wall thickening and the maintenance of lumen circumference, with reduction in calculated tangential wall stress. Whether bFGF directly modulates the remodeling process or stimulates the synthesis/release of other mediating agents remains to be elucidated.
We opted to use an adenoviral vector that has a short half-life. The reasons for selecting this vector are (1) the vector itself is engineered to be replication deficient, (2) the transgene does not incorporate into the host genome, and (3) the immune system of the host eventually destroys the adenovirus. 18 The transgene is present for only 10 to 14 days in our rabbit model, but the results of this study show a sustained effect in the alteration of the remodeling process, at least up to 2 months after the transfection and grafting. Therefore the major potentially beneficial effects of the ASbFGF must take place or be initiated during those first 2 weeks after the grafting.
In summary, we have demonstrated that the inhibition of bFGF reduces tangential stress and promotes the orderly arrangement of cells and matrix in the AVG wall. These potentially beneficial effects are sustained for at least 2 months. We propose that adenovirally mediated ASbFGF gene therapy offers a single, local treatment that may represent an effective strategy in limiting vein graft failure. A and B) have an arbitrary orientation to each other and the endothelial cells lining the lumen. The SMCs and elastin fibers of the Ad.ASbFGFtreated grafts (C) are parallel to each other and circumferentially arrayed relative to the lumen in cross section. The criterion for the determination of the medial/adventitial border is the presence of capillaries and other vascular structures that are located only in the adventitia (elastin-collagen stain; original magnification, ×250). 
